These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2766181)

  • 1. A community survey of Parkinson's disease.
    Snow B; Wiens M; Hertzman C; Calne D
    CMAJ; 1989 Sep; 141(5):418-22. PubMed ID: 2766181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Parkinson's disease in Northern Jordan.
    Alrefai A; Habahbih M; Alkhawajah M; Darwish M; Batayha W; Khader Y; El-Salem K
    Clin Neurol Neurosurg; 2009 Dec; 111(10):812-5. PubMed ID: 19733962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Young onset Parkinson's disease.
    Quinn N; Critchley P; Marsden CD
    Mov Disord; 1987; 2(2):73-91. PubMed ID: 3504266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
    Hely MA; Morris JG; Reid WG; Trafficante R
    Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease.
    Sturman MM; Vaillancourt DE; Metman LV; Bakay RA; Corcos DM
    Brain; 2004 Sep; 127(Pt 9):2131-43. PubMed ID: 15240437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nosography of Parkinson's disease.
    Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1986; 22():119-28. PubMed ID: 3465866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.
    Diederich NJ; Moore CG; Leurgans SE; Chmura TA; Goetz CG
    Arch Neurol; 2003 Apr; 60(4):529-33. PubMed ID: 12707066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical course of patients with idiopathic Parkinson's disease.
    Roos RA; Jongen JC; van der Velde EA
    Mov Disord; 1996 May; 11(3):236-42. PubMed ID: 8723138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods.
    Harris MA; Koehoorn M; Teschke K
    Parkinsonism Relat Disord; 2011 Jul; 17(6):464-9. PubMed ID: 21531606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Punding prevalence in Parkinson's disease.
    Miyasaki JM; Al Hassan K; Lang AE; Voon V
    Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics of Parkinson's disease in natural population].
    Huang JB; Zhang ZX; Wu JX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Feb; 23(1):19-22. PubMed ID: 12905811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early combination therapy with bromocriptine and levodopa in Parkinson's disease.
    Factor SA; Weiner WJ
    Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epidemiology of Parkinson's disease in the county of Rogaland, Norway.
    Tandberg E; Larsen JP; Nessler EG; Riise T; Aarli JA
    Mov Disord; 1995 Sep; 10(5):541-9. PubMed ID: 8552103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Parkinson's disease a homogeneous disorder--what is the burden of Parkinson's disease in India.
    Ghosh B; Mishra A; Sengupta P
    J Indian Med Assoc; 2005 Mar; 103(3):146, 148, 150 passim. PubMed ID: 16173291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.